Fig. 2: Longitudinal capecitabine doses and CEA-based responses of the patients who reached efficacy-driven CURATE.AI dose recommendations.

Effected dose of capecitabine in each cycle vs patient response as measured with longitudinal CEA changes. Patients’ CURATE.AI profiles were generated based on the initial effected dose-CEA response data pairs. Each patient had their own, personalized CURATE.AI profile generated based on their own data only. Standard-of-care (SOC) doses for each patient and each regimen are listed under the regimen’s name. A Patient CURATE002 was diagnosed with sigmoid adenocarcinoma with metastasis to liver and lung and was treated with XELOX. B Patient CURATE007 was diagnosed with colorectal cancer with metastasis to liver and was treated with XELIRI and bevacizumab. C Patient CURATE011 was diagnosed with rectosigmoid cancer and was treated with XELOX. Details of the three patients’ treatment are described in the Supplementary Results. SOC stands for standard-of-care; CT (*) stands for computer tomography; BID means twice a day; PR, SD, and PD stand for partial response, stable disease, and progressive disease, respectively, according to the RECIST criteria; CEA stands for carcinoembryonic antigen. Cap. indicates single-agent capecitabine; XELOX is capecitabine in combination with oxaliplatin; XELIRI is capecitabine in combination with irinotecan.